Multimorbidity or Polypharmacy: Two Sides of the Same Coin?
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Polypharmacy, broadly defined as the chronic co-prescription of several drugs [1], has long been recognized as problematic. The greater the number of medicines a patient takes, the greater the risk of adverse effects of any one medicine, and the greater the risk of drug–drug interactions. Thus, polypharmacy is an accepted risk for poor health outcomes, including hospitalizations and mortality [2]. The number of drugs per patient (or polypharmacy) has come to be used as a measure of potentially hazardous professional behaviour, and is sometimes used in conjunction with the term ‘inappropriate prescribing’. Nonetheless, the prevalence of polypharmacy is rising inexorably [3]. This rise is driven, principally, by the rising prevalence of multimorbidity, i.e. the co-occurrence of two or more chronic long-term diseases or conditions in one patient [4]. The issue is compounded by clinical guidelines that advocate the use of several medicines in the management of individual diseases and their associated risk factors [5]. The result is a dilemma for prescribers: on the one hand there is the need to keep the number of medicines to a minimum, while on the other ensuring that the patient receives what evidence-based guidelines advocate as being in their best interest [6]. Journal of Comorbidity 2015;5(1):29–31
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Michie, S., van Stralen, M. M., & West, R. (2011) · Implementation Science · doi:10.1186/1748-5908-6-42 · Cited by 13,697
Clyne, B., Bradley, M. C., Hughes, C. M., Clear, D., McDonnell, R., Williams, D., Fahey, T., & Smith, S. M. (2013) · BMC Health Services Research · doi:10.1186/1472-6963-13-307 · Cited by 58
Cited by
ESPEN guidelines on nutritional support for polymorbid internal medicine patients
Gomes, F., Schuetz, P., Bounoure, L., Austin, P., Ballesteros-Pomar, M., Cederholm, T., Fletcher, J., Laviano, A., Norman, K., Poulia, K.-A., et al. (2018) · Clinical Nutrition · doi:10.1016/j.clnu.2017.06.025 · Cited by 363
Prevalence of multimorbidity and polypharmacy among adults and older adults: a systematic review
Nicholson, K., Liu, W., Fitzpatrick, D., Hardacre, K. A., Roberts, S., Salerno, J., Stranges, S., Fortin, M., & Mangin, D. (2024) · The Lancet Healthy Longevity · doi:10.1016/s2666-7568(24)00007-2 · Cited by 263
ESPEN guideline on nutritional support for polymorbid medical inpatients
Wunderle, C., Gomes, F., Schuetz, P., Stumpf, F., Austin, P., Ballesteros-Pomar, M. D., Cederholm, T., Fletcher, J., Laviano, A., Norman, K., et al. (2023) · Clinical Nutrition · doi:10.1016/j.clnu.2023.06.023 · Cited by 105
“…in the study population as being more than 1.5 a mean number of diseases or drugs (medications) over 1.5 Polypharmacy is considered to be an important and acceptable marker of polymorbidity, with polypharmacy and polymorbidity having been described as being “ two sides of the same coin ” [13].”
InfluentialSlattery, B. W., O’Connor, L. L., Haugh, S., Barrett, K., Francis, K., Dwyer, C. P., O’Higgins, S., Caes, L., Egan, J., & McGuire, B. E. (2019) · BMJ Open · doi:10.1136/bmjopen-2016-012671 · Cited by 3
“3% of the population are reported to have multimorbidity.(6) Indeed, prevalence rates of multimorbidity vary between subsets of different populations and are often found to be higher for those people who attend medical services.”
Background
Metadata
- Authors
- Sinnott, C., & Bradley, C. P.
- Venue
- Journal of Comorbidity
- Publisher
- SAGE Publications
- Published
- 2015-01
- Volume
- 5
- Issue
- 1
- Pages
- 29-31
- ISSN
- 2235-042X (ISSN-L)
- OpenAlex
- W2093574323
- Cited by
- 53
- References
- 2
- FWCI
- 1.06
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Multimorbidity or Polypharmacy: Two Sides of the Same Coin? https://app.cochat.ai/papers/10.15256/joc.2015.5.51
- The paper
- Sinnott, C., & Bradley, C. P. (2015). Multimorbidity or Polypharmacy: Two Sides of the Same Coin? Journal of Comorbidity. https://doi.org/10.15256/joc.2015.5.51
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.